UBS raised the firm’s price target on Stryker (SYK) to $438 from $421 and keeps a Neutral rating on the shares. The firm’s estimates move higher as product momentum continues, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $450 from $436 at Baird
- Stryker’s Strong Performance and Growth Potential Justifies Buy Rating Despite High Valuation
- Stryker’s Strong Financial Performance and Strategic Initiatives Lead to Buy Rating
- Stryker Corp Reports Strong Q2 2025 Earnings Growth
- Stryker’s Strong Financial Performance and Optimistic Outlook Justify Buy Rating